CHICAGO – July 23, 2020 – EVERSANA™, the main supplier of world industrial providers to the life sciences business, right this moment introduced a partnership with the Institute for Clinical and Economic Review (ICER) to advance requirements for the utilization of clear, replicable and sturdy oblique therapy comparisons in well being know-how assessments.
ICER is an impartial nonprofit analysis institute that produces influential drug assessments and different critiques on the comparative medical effectiveness and cost-effectiveness of well being care interventions. ICER will use EVERSANA’s proprietary know-how as the popular platform for conducting oblique therapy comparisons to acquire comparative effectiveness knowledge within the absence of head-to-head medical trials. The group started testing EVERSANA’s knowledge analytics and proof synthesis platform in early 2020.
Indicative of EVERSANA’s rising management in Data and Analytics, together with Health Economics and Outcomes Research (HEOR), EVERSANA’s web-based platform combines state-of-the-art oblique comparability strategies with modern computing know-how to not directly examine therapies that haven’t been in contrast straight in medical trials. EVERSANA’s proprietary platform can incorporate each medical trial and real-world knowledge, and the strategies employed are clear and have been scientifically validated by main world consultants and benchmarked in opposition to requirements set by well being know-how evaluation companies, payers and regulatory our bodies.
“Our partnership with ICER validates the continued need for novel methods and technology to assess comparative effectiveness of treatments in the absence of clinical trials,” mentioned Chris Cameron, MSc, PhD, Senior Vice President, Data Analytics & Evidence Synthesis at EVERSANA. “Together we’ll continue to advance methods and technology for conducting world-class comparative clinical assessments that will help bring new medical treatments to patients in need.”
The partnership builds on each organizations’ continued dedication to advancing the appliance and transparency of oblique therapy comparability strategies. In late 2019, EVERSANA acquired Canada-based Cornerstone Research Group, a frontrunner in oblique therapy comparisons and HEOR providers. The firm additionally just lately launched its Data & Analytics enterprise unit in April 2020.
ICER will proceed its dedication to leveraging oblique therapy comparisons to enrich different sources of data utilized in its worth assessments, furthering the group’s mission of catalyzing a motion towards honest pricing, honest entry and future innovation throughout the U.S. well being care system.
“EVERSANA’s platform will make us more efficient in how we conduct high-quality and reproducible indirect treatment comparisons,” mentioned Foluso Agboola, MBBS, MPH, Director of Evidence Synthesis for ICER. “They’ve built a best-in-class technology that will help us advance many ongoing initiatives across the U.S. and further support our mission.”
For extra info, go to eversana.com.
EVERSANA™ is the main supplier of world providers to the life sciences business. The firm’s built-in options are rooted within the affected person expertise and span all phases of the product lifecycle to ship long-term, sustainable worth for sufferers, prescribers, channel companions and payers. The firm serves greater than 500 organizations, together with revolutionary start-ups and established pharmaceutical firms, to advance life science options for a more healthy world. To be taught extra about EVERSANA, go to eversana.com or join by LinkedIn and Twitter.